Metabolic syndrome and risk of stroke

Clinical Cornerstone

Volumn 6, Issue 3 SUPPL. 1, 2004, Pages

  Brown, William Virgil ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; DIABETES MELLITUS; HUMAN; METABOLIC SYNDROME X; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; RISK FACTOR;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; CHEMOPREVENTION; DIABETES MELLITUS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; METABOLIC SYNDROME X; PREVALENCE; RISK FACTORS;

EID: 17844392653     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(04)80095-4     Document Type: Article

References (28)

1. Heart Disease and Stroke Statistics-2004 Update (2003), American Heart Association, Dallas, Tex
2. Murray C.J., and López A.D. Mortality by cause for eight regions of the world: Global burden of disease study. Lancet 349 (1997) 1269-1276
3. Gil-Nunez A.C., and Villanueva J.A. Advantages of lipid-lowering therapy in cerebral ischemia: Role of HMG-CoA reductase inhibitors. Cerebrovasc Dis 11 Suppl 1 (2001) 85-95
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in, Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
5. Klein B.E., Klein R., and Lee K.E. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care 25 (2002) 1790-1794
6. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
7. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
8. Olijhoek J.K., van der Graaf Y., Banga J.D., et al. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 25 (2004) 342-348
9. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
10. Iso H., Jacobs Jr. D.R., Wentworth D., et al., MRFIT Research Group. Serum cholesterol levels and six year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med 320 (1989) 904-910
11. Lindenstrom E., Boysen G., and Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: The Copenhagen City Heart Study. BMJ 309 (1994) 11-15
12. Brewer Jr. H.B. Hypertriglyceridemia: Changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Am J Cardiol 83 (1999) 3-12
13. Folsom A.R., Rasmussen M.L., Chambless L.E., et al. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. Diabetes Care 22 (1999) 1077-1083
14. Scott C.L. Diagnosis, prevention, and intervention for the metabolic syndrome. Am J Cardiol 92 Suppl 1A (2003) 35i-42i
15. Gorelick P.B. Stroke prevention therapy beyond antithrombotics: Unifying mechanisms in ischemic stroke pathogenesis and implications for therapy. Stroke 33 (2002) 862-875
16. Schiffrin E.L., and (CIHR) Multidisciplinary Research Group on Hypertension. Beyond blood pressure: The endothelium and atherosclerosis progression. Am J Hypertens 15 Suppl 1 (2002) S115-S122
17. Ridker P.M. High-sensitivity C-reactive protein and cardiovascular risk: Rationale for screening and primary prevention. Am J Cardiol 92 (2003) 17-22
18. Napoli M.D., Papa F., and Bocola V. C-reactive protein in ischemic stroke: An independent prognostic factor. Stroke 32 (2001) 917-924
19. Sowers J.R. Recommendations for special populations: Diabetes mellitus and the metabolic syndrome. Am J Hypertens 16 Suppl 1 (2003) 41S-45S
20. Linton M.F., and Fazio S. A practical approach to risk assessment to prevent coronary artery disease and its complications. Am J Cardiol 92 Suppl 1A (2003) 19i-26i
21. Milani R.V. Lipid and statin effects on stroke and dementia. Am J Geriatr Cardiol 13 Suppl 1 (2004) 25-28
22. Pedersen T.R., Kjekshus J., Pyorala K., et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 81 (1998) 333-335
23. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
24. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360 (2002) 7-22
25. de Lemos A.J., Blazing M.A., Wiviott S.D., et al., A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z Trial. JAMA 292 (2004) 1307-1316
26. Colhoun H.M., Thomason M.J., Mackness M.I., et al. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med 19 (2002) 201-211
27. Bedi A., and Flaker G.C. How do HMG-CoA reductase inhibitors prevent stroke?. Am J Cardiovasc Drugs 2 (2002) 7-14
28. Averna M., and Verde A.L. Statins and metabolic syndrome. Int Congress Series 1253 (2003) 243-246